Immune cell therapy shows promise for tough leukemia cases

NCT ID NCT05358808

Terminated Disease control Sponsor: TC Biopharm Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a treatment called TCB008, made from donated immune cells, for adults with acute myeloid leukemia (AML) that came back or didn't respond to standard therapy. The goal was to see if it could reduce cancer cells in the bone marrow. The trial was stopped early, but the results help researchers understand how this type of cell therapy might work for AML.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Bristol and Weston NHS foundation trust

Bristol, BS2 8ED, United Kingdom
Cardiff and Vale University LHB

Cardiff, CF14 4HH, United Kingdom
Guys&St Thomas NHS foundation Trust

London, SE1 7EH, United Kingdom
Kings College Hospital

London, SE5 9RS, United Kingdom
Queen Elizabeth University Hospital

Glasgow, G51 4TF, United Kingdom
Royal Marsden Hospital

London, SW3 6JJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.